Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthofix Medical (OFIX) Short-term Investments (2023 - 2025)

Historic Short-term Investments for Orthofix Medical (OFIX) over the last 5 years, with Q3 2025 value amounting to $3.1 million.

  • Orthofix Medical's Short-term Investments rose 2344.0% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year increase of 2344.0%. This contributed to the annual value of $2.5 million for FY2024, which is 4623.66% down from last year.
  • According to the latest figures from Q3 2025, Orthofix Medical's Short-term Investments is $3.1 million, which was up 2344.0% from $3.1 million recorded in Q2 2025.
  • Orthofix Medical's Short-term Investments' 5-year high stood at $4.6 million during Q4 2023, with a 5-year trough of $2.5 million in Q1 2024.
  • Over the past 3 years, Orthofix Medical's median Short-term Investments value was $2.5 million (recorded in 2024), while the average stood at $2.9 million.
  • Its Short-term Investments has fluctuated over the past 5 years, first crashed by 4623.66% in 2024, then surged by 2344.0% in 2025.
  • Orthofix Medical's Short-term Investments (Quarter) stood at $4.6 million in 2023, then tumbled by 46.24% to $2.5 million in 2024, then increased by 23.44% to $3.1 million in 2025.
  • Its Short-term Investments stands at $3.1 million for Q3 2025, versus $3.1 million for Q2 2025 and $2.5 million for Q1 2025.